

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**MINGYUAN MEDICARE DEVELOPMENT COMPANY LIMITED**

**銘源醫療發展有限公司\***

*(Incorporated in Bermuda with limited liability)*

**(Stock code: 0233)**

**INSIDE INFORMATION**

This announcement is made by Mingyuan Medicare Development Company Limited (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance.

Reference is made to the Company’s announcement dated 21 December 2016 in which the Company announced that, among other things, a Writ with Indorsement of Claim was issued by the Company and its subsidiaries Shanghai HealthDigit and SHMY Biochips against Deloitte (the “**Writ**”), the former auditor of the Company and its subsidiaries, in the High Court of Hong Kong.

Same references as to the abbreviations and descriptions used in the Company’s announcement dated 21 December 2016 are being adopted in this announcement.

The Company wishes to inform shareholders that a full statement of claim in relation to the Writ has been filed and served on Deloitte on 3 October 2017.

Shareholders will be informed of further development on the aforementioned proceedings.

*\* For identification purpose only*

Trading in shares of the Company will remain suspended pending satisfaction of the resumption conditions imposed by the Stock Exchange.

By Order of the Board  
**Mingyuan Medicare Development Company Limited**  
**LAM Ping Cheung**  
*Chairman*

Hong Kong, 3 October 2017

*As at the date of this announcement, the Board comprises (i) Mr. Lam Ping Cheung and Mr. Hui Yip Wing as executive Directors; (ii) Ms. Chan Mee Sze, Mr. Lam Suk Ping, Mr. Cheung Chi Ming and Ms. Fan Stephanie Winnie as independent non-executive Directors.*